VIVUS, Inc. (VVUS) News

VIVUS, Inc. (VVUS): $0.47

0.05 (-10.29%)

POWR Rating

Component Grades

Momentum

NR

Stability

NR

Sentiment

Quality

NR

Add VVUS to Watchlist
Sign Up

Industry: Medical - Pharmaceuticals

Industry

NR

Ranked


in industry

Filter VVUS News Items

VVUS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest VVUS News From Around the Web

Below are the latest news stories about Vivus Inc that investors may wish to consider to help them evaluate VVUS as an investment opportunity.

Vivus moves closer to emerging from bankruptcy

Vivus (VVUS) plummets 26% premarket after completing the solicitation of an in-court prepackaged plan of reorganization, under which IEH Biopharma will take 100% ownership of the company (the “Prepackaged Plan”), ahead of its Chapter 11 filing.The company solicited IEH as the only holder of claims and has received IEH’s voting in favor of...

Seeking Alpha | July 8, 2020

The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) AbbVie Inc (NYSE: ABBV ) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) argenx SE – ADR (NASDAQ: ARGX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (FDA approved the cellulitis drug it had licensed to Endo International PLC (NASDAQ: ENDP )) Cerus Corporation (NASDAQ: CERS ) (announced study results demonstrating that its INTERCEPT Blood System inactivates SARS-CoV-2 in plasma components intended for transfusion) Corvus Pharma...

Benzinga | July 8, 2020

VIVUS Completes Solicitation for In-Court Reorganization Plan to Become a Wholly Owned Subsidiary of IEH Biopharma LLC

VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has completed the solicitation of an in-court prepackaged plan of reorganization, under which IEH Biopharma LLC (“IEH”) will take 100% ownership of VIVUS (the “Prepackaged Plan”), ahead of its July 7, 2020 chapter 11 filing. The Company solicited IEH―as the only holder of claims in classes entitled to vote on the Prepackaged Plan―and has received IEH’s ballots voting in favor of the Prepackaged Plan in accordance with the amended and restated Restructuring Support Agreement executed by the Company and IEH on July 6, 2020.

Yahoo | July 7, 2020

VVUS: Enterprise Valuation Update

By John Vandermosten, CFA NASDAQ:VVUS READ THE FULL VVUS RESEARCH REPORT Debt Restructuring In May 2013, Vivus, Inc. (NASDAQ:VVUS) closed offerings of $250 million of 4.5% convertible debt that became due in May 2020. The conversion rate of the notes is 6.73038 per $1,000 of face value leaving them well out of the money and unable to convert. Without conversion, the notes remained as debt and

Yahoo | June 10, 2020

Vivus files for equity offering

VIVUS (VVUS) has filed a preliminary prospectus for a public offering of stock and warrants of up to ~$186M. Prices, volumes and terms have yet to be determined.Shares down 3% premarket on light volume....

Seeking Alpha | June 9, 2020

VIVUS Announces Updated Agreement with Icahn Enterprises Holdings L.P.

VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has updated its agreement regarding its corporate debt with Icahn Enterprises Holdings L.P. (dba IEH Biopharma LLC), which holds a principal amount of approximately $170.2 million of the Company’s Convertible Senior Notes. Under the terms of the agreement, the Company will continue to work with IEH Biopharma on an exclusive basis in respect of any restructuring, financing or other material transaction concerning the Company or its assets, with the exception that the Company is granted a 30-day period to refinance and pay in full in cash all amounts due and owing under the Convertible Senior Notes to IEH Biopharma.

Yahoo | June 2, 2020

Edited Transcript of VVUS earnings conference call or presentation 6-May-20 8:30pm GMT

Q1 2020 Vivus Inc Earnings Call

Yahoo | May 23, 2020

VVUS: First Quarter 2020 Results

By John Vandermosten, CFA NASDAQ:VVUS Vivus, Inc. (NASDAQ:VVUS) released first quarter 2020 results on May 6, 2020 and provided an update of financial and operational results for the period. During the first quarter of the year, total revenues were up 22% to $19.6 million on a year over year basis and up 14% sequentially. First quarter earnings were ($0.49) per share and adjusted earnings ($0.15)

Yahoo | May 8, 2020

VIVUS Reports First Quarter 2020 Financial Results

Company to host conference call today at 4:30pm ET CAMPBELL, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a…

GlobeNewswire | May 6, 2020

VIVUS Announces Agreement with IEH Biopharma LLC Granting the Company a 30-Day Grace Period to Restructure its Corporate Debt

CAMPBELL, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced an agreement…

GlobeNewswire | May 1, 2020


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!